Therapeutic Efficacy and Minimum Cost Analysis of Two Chemotherapeutic Regimens for the First Line Treatment of Advance Gastric Cancer
10.6039/j.issn.1001-0408.2015.26.04
- VernacularTitle:两种化疗方案一线治疗晚期胃癌的疗效和最小成本分析
- Author:
Wenjuan WANG
;
Qiong WANG
;
Xiaojun LIU
- Publication Type:Journal Article
- Keywords:
Advanced gastric cancer;
Tegafur gimeracil oteracil potassium capsule;
Chemotherapy;
Pharmacoeconomics;
Min-imum cost analysis
- From:
China Pharmacy
2015;(26):3617-3619
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To evaluate clinical efficacy and the effect of pharmacoeconomics of two chemotherapeutic regimens for the first line treatment of advanced gastric cancer. METHODS:98 patients with advanced gastric cancer receiving SOX or FLO regimen as first line chemotherapy in our hospital were enrolled. According to chemotherapy grouping,short-term efficacy,toxic re-action and pharmacoeconomics effect were analyzed and compared between 2 groups. RESULTS:There were a total of 55 patients in SOX group,with effective rate of 38.18%;43 patients in FLO group,with effective rate of 32.56%;there was no statistical sig-nificance in effective rate between 2 groups(P>0.05). There was no statistical significance in toxicities between 2 groups,includ-ing nausea and vomiting,neurotoxicity and neutropenia(P>0.05). The total cost of FLO regimen group was 9 136.98 yuan,while that of SOX regimen group was 12 345.97 yuan. Using minimum cost method,FLO regimen was superior to SOX regimen regard-ing the economical index. CONCLUSIONS:SOX and FLO regimen have no significant difference for the first-line treatment of ad-vanced gastric cancer in terms of response rate and toxicities. Taking into account the parmocyeconomics,FOL regimen is superior to SOX regimen.
